Full-Year Revenue Growth
FY2025 revenue of $6.2B, up 5.3% underlying (6.1% reported), ahead of guidance; 2022–2025 revenue CAGR of 5.7%.
Smith & Nephew Snats
· SNN
March 2nd, 2026
Summary
- Earnings Call Date:
- 2026-03-02
- Change Since:
- -14.13%
- Next Earnings Date:
- 2026-08-04
Earnings Call Sentiment
PositiveThe call conveyed strong execution and momentum: double-digit improvement in key profitability and cash metrics for FY2025 (margin expansion, $840M free cash flow, adjusted EPS +21%), broad-based revenue growth across business units, record adoption of CORI robotics, and clear cost-savings progress. Management provided constructive FY2026 guidance (~6% organic revenue growth, ~8% trading profit growth) and a disciplined capital allocation approach including targeted M&A (Integrity) aligned with strategy. Offsetting these positives are significant, but largely manageable, near-term headwinds: China VBP effects (now smaller on top line but still weighing on profit), CMS skin-substitute reimbursement changes (material near-term pressure on that subcategory), tariff and reimbursement impacts, and a one-off $159M portfolio rationalization charge. Overall the positives (growth, margin expansion, cash generation, innovation pipeline and cost savings) materially outweigh the near-term challenges and one-off charges, with a credible plan to offset headwinds and deliver further improvement over the medium term.
Company Guidance
Smith & Nephew guided 2026 to around 6% organic revenue growth and roughly 8% organic trading profit growth (with trading profit expected to grow ahead of revenue), and advised total trading profit of about $1.3 billion including the Integrity Orthopaedics acquisition (marginally dilutive in 2026, broadly neutral in 2027 and accretive in 2028). Management expects free cash flow of ~ $800 million in 2026, group ROIC >10% excluding Integrity, and finished 2025 with leverage of ~1.7x adjusted net debt/EBITDA (buybacks to be considered subject to a ~2x target), while maintaining a dividend payout ratio of 35–40%. Guidance is phased to a stronger second half (H1 revenue growth ~4.5–5% and H2 ~7.5–8%; profit growth H1 ~5.5–6% and H2 ~9–10%), factors in one fewer trading day in Q1 and one extra in Q4, and assumes headwinds of c.$60m from tariffs (vs $17m in 2025) and $20–40m incremental impact from wound reimbursement that management expects to more than offset via ~ $150m of savings in 2026 plus revenue leverage. The company also reiterated its mid‑term RISE ambitions of 6–7% organic revenue CAGR, 9–10% trading profit CAGR, >$1bn free cash flow in 2028 and 12–13% ROIC by 2028.
Strong Q4 Performance
Q4 revenue of $1.7B, up 6.2% underlying and 8.3% reported (210 bps FX tailwind); average daily sales growth of 4.5% and broad-based regional growth (U.S. +5.6%, other established +7.2%, emerging +6.4%).
Margin Expansion and Trading Profit
Trading profit rose to $1.2B for the year (+$162M year-on-year) and trading margin expanded 160 basis points to 19.7% in FY2025 (gross margin 70.9%, +60 bps).
Cash Generation and Returns
Free cash flow of $840M, up 52.5% year-on-year and well ahead of initial guidance (> $600M); net debt $2.76B with leverage ~1.7x adjusted net debt/EBITDA; ROIC improved to 8.3% (9.9% excluding portfolio rationalization).
Operational Progress and Cost Savings
Cumulative efficiency savings of $280M achieved to end-2025 against a $325–375M by-2027 target; 160 bps FY25 margin expansion driven by enterprise-wide cost savings, manufacturing optimization, productivity and portfolio rationalization; group days sales inventory reduced materially (group DSI down 21 days excl. rationalization, 51 days incl.).
Innovation-led Growth
Over 60% of 2025 growth came from products launched in the last five years; 44 product launches over the last 3 years and guidance to launch 16 products in 2026; record CORI placements globally with 45% of CORI placements in ASCs and CORI-associated accounts showing Knee growth ~850 bps higher.
Portfolio and Capital Actions
Completed $500M share buyback in H2 2025; adjusted EPS grew 21% to $1.02 (benefitting from buyback); full-year dividend proposed +4.3% to $0.391; announced acquisition of Integrity Orthopaedics (up to $450M) to strengthen shoulder/rotator cuff franchise.
Deepak Nath
Good morning. Welcome to the Smith & Nephew Q4 and Full Year '25 Results Presentation. I'm Deepak Nath, I'm the Chief Executive Officer, and joining me is John Rogers, our CFO. I'm pleased to report a strong finish to 2025, delivering results at the high end of our guidance on revenue growth, margin and free cash flow. For the full year, underlying revenue growth of 5.3% and importantly, all three of our business units grew by over 5%. Sports Medicine & ENT and in particular, Joint Repair within that had another strong year. And in Orthopaedics, we saw meaningful progress in our U.S. recon business, particularly Hips and in Trauma.
When there's more work to do in U.S. Knees, our OUS business, Knees business has remained strong throughout the year. So we had a record year of CORI placements globally and saw continued growth in adoption and utilization of our robot. Advanced Wound Management also had a good performance in 2025, driven by growth in AWD and Bioactives. Innovation remains central to our strategy with over 60% of our growth in 2025 came from products we've launched in the last 5 years. And innovations in all three business units delivered double-digit growth for the year, including Q-FIX, REGENETEN, FASTSEAL, LEGION CONCELOC, CATALYSTEM, EVOS, AETOS, PICO, and LEAF. On profitability, we saw 160 basis points of margin expansion, driven by our enterprise-wide cost savings program and the benefits of all the work we've done in our Orthopedics business dropping through to our P&L. This includes optimizing our manufacturing network, improving productivity, introducin...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free